HOME >> BIOLOGY >> NEWS
AAAS Cautiously Optimistic Of R & D Budget; Warns Of Slant Toward Health Research And Reliance On Tobacco Settlement

The significant increases in funding for R&D programs called for in President Clinton's FY 1999 budget proposal are encouraging, but uneven and heavily dependent upon revenues from an undetermined tobacco settlement, according to a preview of the annual budget analysis released today by the American Association for the Advancement of Science (AAAS).

The AAAS analysis raises concerns about the source of the increases slated for the National Institutes of Health (NIH), the National Science Foundation (NSF), and other R&D funding agencies. A major portion would come from the Research Fund for America, which will be built from tobacco settlement revenues. If a settlement is not reached, the White House may have to propose alternate funding sources for the increases, and may be forced to dip into the budget surplus, go beyond the spending caps, or reallocate money intended to fund other programs.

Another concern in the report is that the bulk of the increases in the President's proposal will support health and life science programs. According to the AAAS analysis, these programs often depend upon the research successes in the physical sciences, engineering and mathematics -- areas which are not slated for major increases. Increases in nondefense R&D are concentrated among only three agencies -- NIH, NSF, and the Department of Energy (DOE).

The AAAS analysis indicates that the President's budget request includes a 2.2 percent or $1.7 billion increase for R&D over the current FY 1998 funding level. After adjusting for inflation, the request represents a slight overall increase of less than one percent. In 1999, nondefense R&D would increase by 5.1 percent to $37.4 billion, while defense R&D would decrease by 0.3 percent to $40.3 billion.

"While the proposal is a positive one, and we are optimistic about it, it's neither balanced or straightforward," said Al Teich, director of the AAAS
'"/>

Contact: Ellen Cooper
ecooper@aaas.org
202-326-6434
American Association for the Advancement of Science
21-Apr-1998


Page: 1 2

Related biology news :

1. Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI
2. Scientists Make Progress Toward Gene Therapy For HIV Infection
3. Structure Of Tumor Necrosis Factor-Alpha-Converting Enzyme Solved - Milestone Toward Rational Drug Design For Rheumatoid Arthritis And Endotoxic Shock
4. Towards A Local Stimulation Of Natural Bypass Growth - Max Planck Scientists Developed New Treatment For Ischemic Heart Disease
5. Researchers Take Major Step Toward Cracking Ebola Code
6. Health of worlds sea lions the focus of Wakefield Symposium
7. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
8. Institute for OneWorld Health nominated for the 2004 World Technology Awards
9. Healthy fats and oils essential to satisfy calorie-conscious consumers
10. Institute for OneWorld Health receives Gates Foundation grant
11. Donaghue Womens Health Investigator Program awards grants to three at Yale

Post Your Comments:
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... pioneering the development of disease modifying therapeutics for ... today the completion of its Series B financing, ... shares and warrants that would represent approximately $2.8M ... investors and new investors supported the raise. ...
(Date:5/22/2013)... N.H. , May 22, 2013  Superior ... the Year 2013" by Business NH Magazine.  For ... Granite State organizations that distinguish themselves with extraordinary ... very proud to receive this honor," said ... Controls.  "As with any recognition, this award is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Genedata, ... industrial biotechnology, drug discovery, and life science research, ... Selector ™ as its bioinformatics platform for ... organisms. Genedata will provide AB Enzymes, one of ... a hosted solution of Genedata Selector accompanied by ...
(Date:5/22/2013)... 22, 2013 AudioNotch ... for tinnitus treatment. AudioNotch is pleased to announce ... clinic locations in both British Columbia and Alberta, ... and hearing services. AudioNotch's tinnitus treatment program is ... entering a Destination Hearing clinic, patients have the ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
Cached News: